You just read:

New Two-Year TREMFYA™ (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance

News provided by

Janssen Research & Development, LLC

Sep 16, 2017, 02:00 ET